WP
KYTX icon

Woodline Partners’s Kyverna Therapeutics KYTX Stock Holding History

Woodline Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.3M Buy
845,325
+182
+0% +$1.52K 0.03% 586
2025
Q4 		$7.94M Buy
845,143
+592,931
+235% +$4.4M 0.03% 521
2025
Q3 		$1.51M Buy
+252,212
New +$1.01M 0.01% 761
2024
Q4 		– Sell
-42,477
Closed -$208K – 1012
2024
Q3 		$208K Sell
42,477
-90,423
-68% -$697K ﹤0.01% 574
2024
Q2 		$997K Sell
132,900
-260,028
-66% -$3.97M 0.01% 462
2024
Q1 		$9.76M Buy
+392,928
New +$11M 0.09% 275

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Woodline Partners's KYTX Position: Q1 2026 in Review

Woodline Partners increased its Kyverna Therapeutics (KYTX) stake by 0.02% in Q1 2026, buying an estimated $1.52K and bringing the position to 845,325 shares worth $7.3M. The position accounts for 0.03% of the portfolio, ranked #586.

Woodline Partners first reported a position in KYTX in Q1 2024 and has held it in 6 quarters since. The position peaked at $9.76M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Woodline Partners held 845,325 shares of Kyverna Therapeutics worth $7.3M as of Q1 2026.
  • Woodline Partners bought 182 Kyverna Therapeutics shares in Q1 2026, an estimated $1.52K.
  • Kyverna Therapeutics made up 0.03% of Woodline Partners's portfolio in Q1 2026, its #586 holding.
  • Woodline Partners first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Woodline Partners's Kyverna Therapeutics position peaked at $9.76M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.